Advertisement

Clinical Drug Investigation

, Volume 16, Issue 1, pp 9–18 | Cite as

Meta- Analyses of Cisapride, Omeprazole and Ranitidine in the Treatment of GORD

Implications for Treating Patient Subgroups
  • Michael Iskedjian
  • Thomas R. Einarson
Clinical Use

Abstract

Objective: Meta-analyses of efficacy results reported in trials of the pharmacological treatment of gastro-oesophageal reflux disease (GORD) with cisapride, omeprazole or ranitidine were performed using randomised, double-blind studies identified by a Medline search covering the years 1984 to 1995.

Results: The overall order of efficacy following 12 weeks of acute treatment was omeprazole 40 mg/day (95% cured) > ranitidine 600 mg/day (81% cured) > cisapride 40 mg/day or ranitidine 300 mg/day (approximately 60% cured). However, important differences emerged regarding efficacy in mild versus severe GORD, and in the frequency of relapse. In mild GORD, the cure rate with cisapride 40 mg/day was greater than the cure rate with ranitidine 300 mg/day (56 vs 38%, respectively), and the cure rate with cisapride 80 mg/day was similar to the cure rate with omeprazole 20 mg/day (82 vs 75%, respectively). In severe GORD, the cure rate with cisapride 80 mg/day was half that of omeprazole 20 mg/day (43 vs 87%, respectively) and comparable with that of ranitidine 300 mg/day (50%). Among patients treated acutely with omeprazole, 6-month relapse rates were 17% with omeprazole 20 mg/day maintenance therapy, but 76 to 80% without maintenance therapy. Among patients treated acutely with cisapride, 6-month relapse rates were 33% with 20 mg/day maintenance therapy and only 40% without maintenance therapy, which compare favourably with those following 6 months– maintenance therapy with ranitidine 300 mg/day (49%).

Conclusion: These results indicate that omeprazole is clearly the treatment of choice for severe GORD, suggest that cisapride may be the treatment of choice for mild GORD, and indicate that either of these two treatments is superior to ranitidine for the prevention of relapse. Further comparative clinical studies are needed, designed specifically to delineate the most appropriate drug therapy for various subgroups of GORD patients.

Keywords

Adis International Limited Cimetidine Omeprazole Ranitidine Maintenance Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Richter JE. Severe reflux esophagitis. Gastroenterol Endocrin Clin North Am 1994; 4(4): 677–98Google Scholar
  2. 2.
    Howden CW, Freston JW. Setting the ‘gold standards’ in the management of gastroesophageal reflux disease. Gastroenterol Today 1996; 6(2): 32–7Google Scholar
  3. 3.
    Fennerty MB, Castell D, Fendrick M, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Arch Intern Med 1996; 156: 477–84PubMedCrossRefGoogle Scholar
  4. 4.
    Klinkenberg-Knol EC, Festen HPM, Meuwissen GM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49(5): 695–710PubMedCrossRefGoogle Scholar
  5. 5.
    Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit acid secretion by blocking H+/K+-ATPase. Nature 1981; 290: 159–61PubMedCrossRefGoogle Scholar
  6. 6.
    Baldi F, Bianchi Porro G, Dobrilla G, et al. Cisapride versus placebo in reflux esophagitis: a multicenter double blind trial. J Clin Gastroenterol 1988; 10: 614–8PubMedCrossRefGoogle Scholar
  7. 7.
    Janisch HD, Huttemann W, Bouzo MH. Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepato-gastroenterology 1988; 35: 125–7PubMedGoogle Scholar
  8. 8.
    Galmiche JP, Grandstatter G, Evreux M, et al. Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind placebo-controlled trial. Gut 1988; 29: 675–81PubMedCrossRefGoogle Scholar
  9. 9.
    Lepoutre L, Van Der Spek P, Vanderlinden I, et al. Healing of grade II and III oesophagitis through motility stimulation with cisapride. Digestion 1990; 45: 109–14PubMedCrossRefGoogle Scholar
  10. 10.
    Galmiche JP, Fraitag B, Filoche B, et al. Double blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990; 35(5): 649–55PubMedCrossRefGoogle Scholar
  11. 11.
    Evreux M, Filoche B, Fournet J, et al. Endoscopic and clinical evaluation of cisapride and cimetidine in reflux oesophagitis. Gastroenterology 1988; 94: A120Google Scholar
  12. 12.
    Maleev A, Mendizova A, Popov P, et al. Cisapride and cimetidine in the treatment of erosive esophagitis. Hepatogastroenterol 1990; 37: 403–7Google Scholar
  13. 13.
    Dodds W, Champion M, Orr W, et al. Oral cisapride in GERD: a double blind placebo controlled multicenter trial. Gastroenterology 1989; 96: A126Google Scholar
  14. 14.
    de Micco M, Berenson M, Wu W, et al. Cisapride in the treatment of GERD: a double blind placebo controlled multicenter dose response trial. Gastroenterology 1992; 102: A59Google Scholar
  15. 15.
    Faraqui S, Sigmund C, Smith R, et al. Cisapride in the treatment of GERD: a double blind placebo controlled multicenter dose response trial. Gastroenterology 1992; 102: A66Google Scholar
  16. 16.
    Inauen W, Emde C, Weber B, et al. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study. Gut 1993; 34: 1025–31PubMedCrossRefGoogle Scholar
  17. 17.
    Spector TD, Thompson SG. The potential and limitation of meta-analysis. J Epidemiol Comm Health 1991; 45: 89–92CrossRefGoogle Scholar
  18. 18.
    Einarson TR, McGhan WF, Bootman JL, et al. Meta-analysis: quantitative integration of independent research results. Am J Hosp Pharm 1985; 42: 1957–64PubMedGoogle Scholar
  19. 19.
    Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiologic studies. Drug Intell Clin Pharm 1988; 22: 813–24PubMedGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88PubMedCrossRefGoogle Scholar
  21. 21.
    Arvanitakis C, Mikopoulos A, Theohairdis A, et al. Cisapride versus ranitidine in the treatment of gastro-oesophageal reflux disease — a comparative randomized double-blind trial. Aliment Pharmacol Ther 1993; 7: 635–41PubMedCrossRefGoogle Scholar
  22. 22.
    Barbier JP, Haccoun JP, Bergmann P, et al. Facteurs pronostiques de la cicatrisation de l'oesophagite par reflux: un essai controle omeprazole versus ranitidine. Ann Gastro-enterol Hepatol 1993; 29(4): 213–8Google Scholar
  23. 23.
    Bate CM, Booth SN, Crowe JP, et al. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993; 7: 501–7PubMedCrossRefGoogle Scholar
  24. 24.
    Bate CM, Keeling PWN, O'Morain C, et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 1990; 31: 968–72PubMedCrossRefGoogle Scholar
  25. 25.
    Bianchi Porro G, Pace F, Peracchia A, et al. Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. J Clin Gastroenterol 1992; 15(3): 192–8CrossRefGoogle Scholar
  26. 26.
    Bovero E, Cheli R, Barbara L, et al. Short-term treatment of reflux oesophagitis with ranitidine 300 mg nocte: Italian multicenter study. Hepatogastroenterology 1987; 34: 155–9PubMedGoogle Scholar
  27. 27.
    Bremner CG, Marks IN, Segal I, et al. Reflux esophagitis therapy: sucralfate versus ranitidine in a double-blind multicenter trial. Am J Med 1991; 91Suppl. 2A: 119S–122SPubMedCrossRefGoogle Scholar
  28. 28.
    Dakkak M, Jones BP, Scott MGB, et al. Comparing the efficacy of cisapride and ranitidine in oesophagitis: a double-blind, parallel group study in general practice. Br J Clin Pract 1994; 48(1): 10–14PubMedGoogle Scholar
  29. 29.
    Dammann HG, Blum AL, Lux G, et al. Omeprazole versus ranitidine in the treatment of reflux oesophagitis. Dig Dis Sci 1986; 31(10 Suppl.): 27SGoogle Scholar
  30. 30.
    Dehn TCB, Sheperd HA, Colin-James D, et al. Double-blind comparison of omeprazole (40 mg qd) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24h pH monitoring. Gut 1990; 31: 509–13PubMedCrossRefGoogle Scholar
  31. 31.
    Dent J, Hetzel DJ, Mackinnon MA, et al. Evaluation of omeprazole in reflux oesophagitis. Scand J Gastroenterol 1989; 24Suppl. 166: 76–82CrossRefGoogle Scholar
  32. 32.
    Euler AR, Murdock RH, Wilson TH, et al. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol 1993; 88(4): 520–4PubMedGoogle Scholar
  33. 33.
    Geldorf H, Hazelhoff B, Often MH. Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. Aliment Pharmacol Ther 1993; 7: 409–15CrossRefGoogle Scholar
  34. 34.
    Goy JA, Maynard JH, Mchaughton WM, et al. Ranitidine and placebo in the treatment of reflux oesophagitis: A double-blind randomized trial. Med J Aust 1983; 2: 558–61PubMedGoogle Scholar
  35. 35.
    Guslandi M. Cimetidine plus cisapride for reflux oesophagitis. Lancet 1988; II: 229CrossRefGoogle Scholar
  36. 36.
    Guslandi M, Testoni PA, Passaretti S, et al. Ranitidine vs meto-clopramide in the medical treatment of reflux oesophagitis. Hepatogastroenterology 1983; 30: 96–8PubMedGoogle Scholar
  37. 37.
    Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis: results of a Scandinavian multicenter trial. Scand J Gastroenterol 1993; 28: 224–8PubMedCrossRefGoogle Scholar
  38. 38.
    Havelund T, Laursen LS, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: double-blind comparative trial. BMJ 1988; 296(9): 89–92PubMedCrossRefGoogle Scholar
  39. 39.
    Hine KR, Holmes GKT, Melikian V, et al. Ranitidine in reflux oesophagitis: a double blind placebo-controlled study. Digestion 1984; 29: 119–23PubMedCrossRefGoogle Scholar
  40. 40.
    Hungin APS, Gunn SD, Bate CM, et al. A comparison of the efficacy of omeprazole 20 mg once daily with ranitidine 150 mg bd in the relief of symptomatic gastroesophageal reflux disease in general practice. Br J Clin Res 1993; 4: 73–88Google Scholar
  41. 41.
    Janisch HD, and the Cisran study group]. A double-blind multi-center trial to compare the efficacy of cisapride (CIS) and ranitidine (RAN) in the acute treatment of gastroesophageal reflux disease (GERD). Gastroenterology} 1986}; 90(5)}Google Scholar
  42. 42.
    Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, et al. Double-blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1987; I: 349–51CrossRefGoogle Scholar
  43. 43.
    Koelz HR, Birchler R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198–205PubMedGoogle Scholar
  44. 44.
    Lehtola J, Niemela S, Martikainen J, et al. Ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis: a placebo-controlled, double-blind study. Scand J Gastroenterol 1986; 21: 175–80PubMedCrossRefGoogle Scholar
  45. 45.
    Masci E, Testoni ME, Passaretti S, et al. Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short term treatment of reflux oesophagitis. Drugs Exp Clin Res 1985; 11(10): 687–92PubMedGoogle Scholar
  46. 46.
    Pace F, Sangaletti O, Bianchi Porro G. Comparison of algicon and ranitidine in the therapy of reflux oesophagitis: preliminary results. Br J Clin Pract 1989; 43Suppl. 66: 59–60Google Scholar
  47. 47.
    Richter JE, Long JF. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. Am J Gastroenterol 1995; 90(3): 423–30PubMedGoogle Scholar
  48. 48.
    Robertson CS, Evans DF, Ledingham SJ, et al. Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 181–90PubMedCrossRefGoogle Scholar
  49. 49.
    Roufail W, Belsito A, Robinson M, et al. Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 1992; 6: 597–607PubMedCrossRefGoogle Scholar
  50. 50.
    Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis: results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 625–32PubMedCrossRefGoogle Scholar
  51. 51.
    Schaub N, Meyrick Thomas J, Misiewicz JJ, et al. Investigation of ranitidine 150 mg bd or 300 mg bd in the treatment of reflux disease. Hepatogastroenterology 1986; 33: 208–13PubMedGoogle Scholar
  52. 52.
    Sherbaniuk R, Wensel R, Bailey R, et al. Ranitidine in the treatment of symptomatic gastroesophageal reflux disease. J Clin Gastroenterol 1984; 6: 9–15PubMedGoogle Scholar
  53. 53.
    Simon B, Mueller P. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. Am J Med 1987; 83Suppl. 3B: 43–7PubMedCrossRefGoogle Scholar
  54. 54.
    Sontag SJ, Hirshowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US multicenter study. Gastroenteroogyl 1992; 102: 109–18Google Scholar
  55. 55.
    VanTrappen G, Ruggeerts L, Schurmans P, et al. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988; 33(5): 523–9PubMedCrossRefGoogle Scholar
  56. 56.
    Wesdorp ICE, Dekker W, Klinkenberg-Knol EC. Treatment of reflux oesophagitis with ranitidine. Gut 1983; 24: 921–4PubMedCrossRefGoogle Scholar
  57. 57.
    Zeitoun P, Rampai P, Barbier P, et al. Omeprazole (20 mg/j) compare a ranitidine (150 mg 2 fois/j) dans le traitement de l'oesophagite par reflux. Resultats d'un essai multicentrique franco-belge, randomize en double insu. Gastroenterol Clin Biol 1982; 13: 457–62Google Scholar
  58. 58.
    Blum AL, Adami B, Bouzo MH, et al. Effect of cisapride on relapse of esophagitis: a multinational, placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993; 38(3): 551–60PubMedCrossRefGoogle Scholar
  59. 59.
    Dent J, Yeomans NDY, MacKinnon M, et al. Omeprazole vs. ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590–8PubMedCrossRefGoogle Scholar
  60. 60.
    Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastro-enterology 1994; 107: 1305–11Google Scholar
  61. 61.
    Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903–12PubMedGoogle Scholar
  62. 62.
    Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopie healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterology 1991; 26: 248–56CrossRefGoogle Scholar
  63. 63.
    Toussaint J, Gossuin A, Deruyttere M, et al. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991; 32: 1280–5PubMedCrossRefGoogle Scholar
  64. 64.
    Tytgat GNJ, Anker Hansen OJ, Carling L, et al. Effect of cisapride on relapse of reflux esophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992; 27: 175–83PubMedCrossRefGoogle Scholar
  65. 65.
    Beck IT, Connon J, Lemire S, et al. Canadian consensus conference on the treatment of gastroesophageal reflux disease. Can J Gastroenterol 1992; 6(5): 277–89Google Scholar
  66. 66.
    Crookes PF, DeMeester TR. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Arch Surg 1996; 131: 1021–2PubMedCrossRefGoogle Scholar
  67. 67.
    Richter JE. Surgery for reflux disease — reflections of a gastroenterologist. N Engl J Med 1992; 326: 825–7PubMedCrossRefGoogle Scholar
  68. 68.
    Perras C, Otten N. Pharmaceutical management of gastroesophageal reflux disease. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Overview: Pharmaceuticals. Issue 1996; 3.2: 1–9Google Scholar
  69. 69.
    Chiba N, de Gara CJ, Berget DW, et al. Rapidity of healing in GERD: a comparison of different drug classes by meta-analysis [abstract]. Gastroenterology 1993; 104: A53Google Scholar
  70. 70.
    Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 1Suppl. 1: 3–7Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Michael Iskedjian
    • 1
  • Thomas R. Einarson
    • 2
  1. 1.PharmIdeas Consulting ServicesHamiltonCanada
  2. 2.Faculty of PharmacyUniversity of TorontoTorontoCanada

Personalised recommendations